InvestorsHub Logo
Followers 19
Posts 2315
Boards Moderated 0
Alias Born 03/12/2013

Re: guardiangel post# 29749

Tuesday, 08/25/2015 12:58:08 PM

Tuesday, August 25, 2015 12:58:08 PM

Post# of 30046
Radient Restructured By A Planned Reverse Merger

Jim is Correct..Pharmigene and Uni-Pharma will merge along with GCDX into the Radient Shell....GCDX is a wholly owned subsidiary of Provista Diagnostics. GCDX will operate North and South American Territories and Arima the territories listed in the Radient/AMDL Diagnostics Inc. and Uni-Pharma Agreement..That agreement ends in June 2018...The Vision of Arima is to EMERGe a/k/a Reverse Merge into Radient shell. Why Radient shell? Uni-Pharma wants full control of DR-70 and CIT...imo


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116432724

VISION

Arima drugs are expected to establish a center of the detection of cancer tumors in the next few years, tumor ablation and anticancer drugs after blood concentration monitoring systems for clinical services and patient treatment of cancer will provide more delicate and more accurate service. In view of the detection of the cancer, the efficacy of cancer treatment and cancer treatment to assess the importance of cancer treatment for as much tumor drug development.

Board Resolution Arima will be completed in 2015 in all internal protracted process review, in 2016 made public accountant unqualified opinions, 2016 public offering and listing Emerging made through 2017 by the Emerging into OTC company.

Successful public offering and listing will give Arima certain corporate social responsibility and care for the clinical needs of the mission, despite an increase in responsibility and burden, but will also strengthen the company and enhance physique to raise social awareness Arima Arima more outstanding talent to join the team. Arima will be able to face greater challenges and to assume more and more large-scale research and development and the market value of new drugs, new medical technologies, new medical devices and new diagnostic techniques of.

Arima drugs in the new wave of the future will continue to adhere to the company's rapid growth over ten years core values:
We provide our customers with the best product and patients;
Return on shareholders' equity investment;
According to Gu Huayu employees;
Arima equal treatment of partners;
To enthusiastic attitude and professional practice self connotation.

http://uni-pharma.com/about-03.html

Milestones

http://uni-pharma.com/about-02.html


Partners

http://uni-pharma.com/about-04.html

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.